Professional technology integration to support the entire R&D process

The development of antibody-drug conjugate (ADC) assays aims to establish a series of in vitro analytical methods to comprehensively evaluate the synergistic function of the three core components of ADCs—antibody, linker, and cytotoxic payload. Unlike simple antibodies or chemotherapeutic agents, the activity of ADCs depends on a multi-step process involving target-specific binding, effective internalization, lysosomal degradation, and payload release. Therefore, the core of its development is to construct a functional analytical platform capable of evaluating these key steps individually or in combination to support the molecular design, potency evaluation, and mechanism studies of ADCs.

1. Definition of Mechanism of Action and Assay Targets

Key Steps Analysis: Identify the ADC action steps to be evaluated: 1) Antigen binding and specificity; 2) Internalization and intracellular transport; 3) Lysosomal degradation and payload release; 4) Payload-mediated cytotoxicity (including bystander effects).

Assay Targets: Determine the focus based on the development stage, such as early candidate molecule screening (emphasizing binding and internalization), potency and cytotoxic efficacy evaluation, linker stability assessment, or bystander effect studies.

2. Construction of Cell Models and Detection Systems

Cell Models:

Target Expression Model: Construct or screen tumor cell lines with high antigen expression as primary pharmacodynamic models.

Negative Control Model:Use homologous cell lines that do not express (or express very low levels of) the antigen to assess target specificity and off-target toxicity.

Bystander Effect Model:Establish co-culture systems of antigen-positive and antigen-negative cells to assess the cytotoxic effect of diffusible payloads.

Reporter System:

Fluorescent/Luminescently Labeled ADCs:Prepare ADC analogs labeled with fluorescent dyes (such as pHrodo™, whose fluorescence is enhanced in acidic lysosomes) or fluorescent proteins (such as pH-sensitive GFP variants) for real-time tracking of internalization and localization.

Reporter Gene Engineered Cells:Construct cells expressing payload-specific reporter genes (such as transcriptional reporter systems activated by tubulin inhibitors) for specific monitoring of the release and action of intracellular active payloads.

3. Development and Optimization of Multifunctional Assay Methods

 Binding and Internalization Assays:

Technology Selection: Flow cytometry (quantitative surface binding and internalization), high-content imaging (visualizing internalization kinetics and subcellular localization), surface plasmon resonance (SPR, quantitative binding kinetics).

Key Optimizations: Temperature (4°C binding vs. 37°C internalization), time course, acid washing step (removing surface antibodies to distinguish internalized portions).

In vitro cytotoxicity assays:

Technology Selection: Cell viability assay (CTG, CellTiter-Glo), colony formation, real-time cell analysis (RTCA).

Key Optimizations: Extended exposure time (typically 72-120 hours, simulating sustained load action), parallel controls with naked antibodies and free loads.

Linker stability and load release assays:

In vitro plasma stability: ADC is added to human or animal plasma, and the content of intact ADC, naked antibody, and free load is quantitatively analyzed using affinity capture LC-MS/MS at different time points.

Intracellular payload release: Using antibodies targeting the payload, the accumulation of intracellular free payloads was detected by immunofluorescence or Western blotting.

4. Data Analysis and Specificity Validation

 Data Analysis: Binding affinity (KD), internalization rate, half-maximal effective concentration (EC₅₀), and maximum cytotoxicity were calculated, and the activity differences between the ADC and control groups were compared.

Specificity Validation:

Target-dependent cytotoxicity was validated using antigen-negative cells.

Functional inhibition was validated by blocking ADC binding with excess soluble antigen.

Lysosome-dependent cytotoxicity was validated by treatment with a lysosomal inhibitor (e.g., bafloxacin A1).

Challenge 1: Differentiating ADC activity from that of naked antibodies or free payloads

Solution:

Establish rigorous controls: Each experiment must be conducted in parallel with isotype naked antibody, free payload (concentration must match the molar concentration of the payload in the ADC), and isotype control ADC (for irrelevant antigens).

Use antigen-negative cells: Verify that the cytotoxicity of ADCs is significantly higher than that of naked antibodies and free payloads only in antigen-positive cells.

Challenge 2: Accurately mimicking the in vivo processes of internalization and payload release

Solution:

Use engineered reporter cells: Constructing reporter cell lines expressing payload-specific response elements (e.g., tubulin perturbation-activated transcriptional reporter systems) can more specifically reflect the release of intracellular bioactive payloads.

Pulse-tracking experimental design: Administer ADC for a short period (e.g., 2-4 hours), followed by culture in drug-free medium to simulate the sustained action of intracellular payloads after rapid in vivo clearance of ADCs. 

Challenge 3: Assessing linker stability

Solution:

Combining orthogonal methods: In vitro plasma stability assays (LC-MS/MS) are combined with intracellular activity assays. Unstable linkers in plasma often lead to reduced in vitro killing efficacy (due to payload loss before reaching target cells), but may increase bystander effects.

Challenge 4: High Background Toxicity (Off-Target Effects)

Solutions:

Optimize DAR and payload: Test ADCs with different drug-to-antibody ratios (DARs) to find the optimal balance between potency and therapeutic window.

Use payloads with weaker bystander effects: If off-target toxicity is the primary concern, consider selecting payloads with lower membrane permeability.

Applications: Screening and optimization of ADC candidate molecules, potency/stability bioassays, mechanism of action studies, biosimilar similarity evaluation, and development of preclinical pharmacodynamic biomarkers.

Trends:

1.More complex in vitro tumor models: Evaluate ADC penetration and killing in 3D tumor spheroids or organoids to better simulate the solid tumor microenvironment.

2.Functional assays of immune cell-targeted ADCs: Develop assays to evaluate the redirection or activation of immune cells (e.g., T cells, macrophages) induced by ADCs.

3.High-dimensional data integration: Combining transcriptomics and proteomics analysis to reveal the cellular response network of ADC treatment.

4.Fine characterization of site-specific ADC coupling: Developing high-resolution analytical methods that can distinguish between species with different DAR values ​​and heterogeneity of coupling sites.

ADC assay development is a multidimensional integrated process, requiring the organic fusion of immunological (binding), cell biological (internalization), and pharmacological (killing) analytical methods. Successful development begins with a profound understanding of the ADC mechanism of action, and based on this, the selection of models and detection techniques that specifically reflect the functional output of each key step. Establishing robust and reliable assays across multiple dimensions, including target specificity, killing efficacy, linker stability, and bystander effects, is the cornerstone of the rational design and optimization of next-generation, highly effective, and safe ADC drugs. The development process should be highly flexible to accommodate the characterization needs of ADC molecules with different mechanisms of action (e.g., cleavable/non-cleavable linkers, membrane-permeable/non-permeable loading).